California's affordable insulin faces slow patient uptake despite availability

California's initiative to offer a more affordable state-branded insulin, CalRx, is facing a paradox: while the drug is available through major retailers and distributors, patient uptake remains limited. Governor Gavin Newsom's health initiative aims to provide a cheaper alternative for uninsured individuals or those struggling with prescription costs, while also influencing market prices with transparent pricing.

In the first seven months of the program, California distributed over 120,000 five-pen packs of CalRx insulin glargine. Each pack has a suggested retail price of $55, significantly lower than the $89 to $411 range for popular brands before consumer discounts. However, the exact number of boxes dispensed to patients by pharmacies is still unknown, according to KFF Health News. Elizabeth Landsberg, director of the California Department of Health Care Access and Information (HCAI), highlighted agreements with three major pharmaceutical wholesalers and four insurers to include CalRx in their formularies.

Despite its presence on platforms like Amazon and Costco, and in some CVS, Walgreens, and Walmart pharmacies, CalRx's arrival in stores has been slow. Many diabetes patients remain unaware of this more affordable option. Geoffrey Joyce, director of health policy at the Schaeffer Center at the University of Southern California, noted that the state's effort currently reaches only a limited portion of the population.

The state-branded insulin, launched on January 1, 2026, was priced by the Governor's office at $45 for pharmacies, with a suggested retail price of up to $55 for a five-pen pack, averaging $11 per unit. This biosimilar insulin glargine is interchangeable with Lantus. The program primarily targets individuals without health coverage or those with high deductibles, though insured patients may also pay less if their plan includes the product. Civica, the non-profit manufacturer partnered with California, operates on a model that avoids rebates or special access programs.

The HCAI had anticipated distribution challenges, noting in January that widespread availability across the state would take time. Insurers' decisions on formularies and pharmacies' stocking choices continue to influence the program's reach, creating significant barriers to its broader adoption.

“

California distributed over 120,000 five-pen packs of insulin glargine during the first seven months of the program.